BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31907738)

  • 1. Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies.
    Doi T; Boku N; Onozawa Y; Takahashi K; Kawaguchi O; Ohtsu A
    Invest New Drugs; 2020 Oct; 38(5):1390-1399. PubMed ID: 31907738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
    Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA
    Oncology; 2016; 90(1):10-20. PubMed ID: 26492090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
    Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A
    Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer.
    Boku N; Muro K; Machida N; Hashigaki S; Kimura N; Suzuki M; Lechuga M; Miyata Y
    Invest New Drugs; 2014 Apr; 32(2):261-70. PubMed ID: 23665950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of aflibercept in combination with docetaxel in Japanese patients with advanced solid malignancies.
    Sunakawa Y; Takahashi K; Kawaguchi O; Yamamoto N
    Invest New Drugs; 2022 Oct; 40(5):1032-1041. PubMed ID: 35771301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
    Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V
    Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours.
    Diaz-Padilla I; Siu LL; San Pedro-Salcedo M; Razak AR; Colevas AD; Shepherd FA; Leighl NB; Neal JW; Thibault A; Liu L; Lisano J; Gao B; Lawson EB; Wakelee HA
    Br J Cancer; 2012 Aug; 107(4):604-11. PubMed ID: 22805331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
    Thai HT; Veyrat-Follet C; Mentré F; Comets E
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.
    Lockhart AC; Rothenberg ML; Dupont J; Cooper W; Chevalier P; Sternas L; Buzenet G; Koehler E; Sosman JA; Schwartz LH; Gultekin DH; Koutcher JA; Donnelly EF; Andal R; Dancy I; Spriggs DR; Tew WP
    J Clin Oncol; 2010 Jan; 28(2):207-14. PubMed ID: 19949018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.
    Tew WP; Gordon M; Murren J; Dupont J; Pezzulli S; Aghajanian C; Sabbatini P; Mendelson D; Schwartz L; Gettinger S; Psyrri A; Cedarbaum JM; Spriggs DR
    Clin Cancer Res; 2010 Jan; 16(1):358-66. PubMed ID: 20028764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations.
    Xu J; Li Y; Sun X; Zhang D; Liu R; Ziti-Ljajic S; Shi D; Xue F; Le Bail N; Xu R
    Invest New Drugs; 2017 Aug; 35(4):463-470. PubMed ID: 28102464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.
    Wang-Gillam A; Tew WP; Rothenberg ML; Dupont J; Cooper W; Sternas L; Buzenet G; Sosman JA; Spriggs DR; Lockhart AC
    Invest New Drugs; 2012 Oct; 30(5):1958-61. PubMed ID: 22002018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.
    Van Cutsem E; Khayat D; Verslype C; Billemont B; Tejpar S; Meric JB; Soussan-Lazard K; Assadourian S; Cartot-Cotton S; Rixe O
    Eur J Cancer; 2013 Jan; 49(1):17-24. PubMed ID: 22921183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.
    Freyer G; Isambert N; You B; Zanetta S; Falandry C; Favier L; Trillet-Lenoir V; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Fumoleau P
    Br J Cancer; 2012 Aug; 107(4):598-603. PubMed ID: 22790797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study.
    Kojima Y; Yoshie R; Kawamoto H; Shimo A; Uejima T; Iwatani T; Motoyoshi A; Kanemaki Y; Boku N; Tsugawa K
    Oncology; 2019; 96(6):309-317. PubMed ID: 30893699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
    Morita S; Nakata B; Tsuji A; Mitachi Y; Shirasaka T; Saji S; Ohashi Y; Sakamoto J; Hirakawa K
    Jpn J Clin Oncol; 2007 Dec; 37(12):924-9. PubMed ID: 18211983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
    Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma.
    Ikeda M; Shiina S; Nakachi K; Mitsunaga S; Shimizu S; Kojima Y; Ueno H; Morizane C; Kondo S; Sakamoto Y; Asaoka Y; Tateishi R; Koike K; Arioka H; Okusaka T
    Invest New Drugs; 2014 Oct; 32(5):928-36. PubMed ID: 24829073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy.
    Shin SJ; Jung M; Jeung HC; Kim HR; Rha SY; Roh JK; Chung HC; Ahn JB
    Invest New Drugs; 2012 Aug; 30(4):1501-10. PubMed ID: 21567184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.